Table 1 Cohorts used to compare long term extrapolations for newly diagnosed multiple myeloma including the number of patients included and data cuts
Data Source | Drug | Mean age of cohort | Years of inclusion | Start date Inclusion | End date Inclusion | Sample Size | Data cuts | Maximum Follow-up (years) | Minimum Potential Follow-up (years) | Horizon RMST (years) | Horizon lifetime RMST (years) |
|---|---|---|---|---|---|---|---|---|---|---|---|
HOVON49 | MP | 74 | 2002–2007 | 09-19-2002 | 07-16-2007 | 168 | 2005, 2008, 2010, 2012 | 3, 6, 8, 10 | n.a.,1,3,5 | 11 | 35 |
HOVON49 | Thal. | 74 | 2002–2007 | 09-19-2002 | 06-27-2007 | 166 | 2005, 2008, 2010, 2012 | 3, 6, 8, 10 | n.a.,1,3,5 | 11 | 35 |
PHAROS | MP | 76 | 2004–2009 | 01-15-2004 | 01-15-2009 | 208 | 2007, 2010, 2012, 2014, 2017 | 3, 6, 8, 10,13 | n.a.,1,3,5,8 | 14 | 35 |
PHAROS | Thal. | 72 | 2005–2010 | 01-01-2005 | 01-01-2010 | 552 | 2008, 2011, 2013, 2015, 2018 | 3, 6, 8, 10, 13 | n.a.,1,3,5,8 | 14 | 35 |
PHAROS | Bort. | 64 | 2006–2011 | 01-01-2006 | 01-01-2011 | 122 | 2009, 2012,2014, 2016, 2019 | 3, 6, 8, 10, 13 | n.a.,1,3,5,8 | 14 | 35 |
NKR+ | Bort. | 74 | 2014–2016 | 01-10-2014 | 01-10-2016 | 637 | 2017, 2020, 2022 | 3, 6, 8 | 1,4,6 | 8 | 35 |